General eCQM Information
| CMS Measure ID | CMS646v1 |
|---|---|
| NQF Number | None |
| Measure Description |
Percentage of patients initially diagnosed with nonmuscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging. |
| Initial Population | All patients initially diagnosed with T1, Tis or high grade Ta nonmuscle invasive bladder cancer and a qualified encounter in the measurement period. |
| Denominator Statement |
Equals Initial population |
| Denominator Exclusions |
Immunosupppressed patients, includes HIV and immunocompromised state. Immunosuppressive drug therapy. Active Tuberculosis. Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease. Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging. |
| Numerator Statement |
Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series. BCG is initiated within 6 months of the bladder cancer staging and overlaps the measurement period. |
| Numerator Exclusions |
None |
| Denominator Exceptions |
Unavailability of BCG |
| Measure Steward | Oregon Urology |
| Measure Scoring | Proportion measure |
| Measure Type | Process measure |
| Improvement Notation |
A higher score is the preferred result and indicates better quality |
| Guidance |
Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines. The BCG dose can be full or partial and can be from any lot or manufacturer. This eCQM is a patient-based measure. This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center for more information on the QDM. |
| Meaningful Measure | Appropriate Use of Healthcare |